…
Sandy Huffaker for The Washington Post via Getty Images Eli Lilly stock could soar 140% by 2028 as millions of…
…
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year.…
The launch of Eli Lillys weight-loss drug Zepbound is going swimmingly in the U.S., Jefferies said Friday.…
Theres a lot of growth still to come for this healthcare behemoth.…
Theres a lot of growth still to come for this healthcare behemoth.…
Das amerikanische Pharma-Unternehmen Eli Lilly schwimmt auf der Erfolgswelle. Der Grund dafür ist vor allem der Hype um einen Wirkstoff:…
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added…
The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Stakeholder rights law firm Johnson Fistel, LLP has launched an…
Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.…
Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.…
Full results from a late-stage study show that patients who stopped taking Eli Lillys (LLY) weight-loss drug for over a…
NEW YORK (dpa-AFX) - Aktuelle Daten zum Abnehmmittel Zepbound (Tirzepatide) haben den in diesem Jahr bislang…
The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…
The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…
Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…
Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…
The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.…
These are the stocks posting the largest moves in midday trading.…
NEW YORK (dpa-AFX Broker) - Die Aktien von Eli Lilly sind am Montag nach einem…
Individuals using Eli Lilly and Co (NYSE:LLY)’s obesity drug Zepbound (tirzepatide) regained weight after they stopped using the treatment, according…
…
Zepbound, which Eli Lilly had hoped would offset the slide in Trulicity sales, had mixed results in a major clinical…
By John Vandermosten, CFA
NASDAQ:ALLR
Early Results - Phase II Stenoparib
Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…
Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…
Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…
Theres no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has…
Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around 50%. Should investors buy either…
Eli Lillys drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.…
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stakeholder rights law firm Johnson Fistel, LLP has launched an…
Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US,…
Eli Lilly & Co.’s new weight-loss drug Zepbound is now available at US pharmacies, offering an alternative to rival medications…
Eli Lillys recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured…
Eli Lillys obesity drug now available in U.S. pharmacies…
Eli Lilly & Co. LLY said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit…
Over the past decade, December been especially kind to Broadcom (AVGO) and Eli Lilly (LLY).…
Pro Research: Wall Street takes on Eli Lillys prospects…
Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this…
Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15…
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…
Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca,…
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and thats good news for…
The Investing Club holds its Morning Meeting every weekday at 10:20 a.m. ET.…
Eli Lilly has a well-rounded business that can be a good fit for all types of investors.…
Investors’ have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight…
…
By John Vandermosten, CFA
NASDAQ:LEXX
READ THE FULL LEXX RESEARCH REPORT
Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with…